Clinical trial registry record

Safety and Efficacy of AM712 in Patients with NAMD

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 12, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05345769
Last registry update
December 12, 2024
Status
Completed
Phase
Phase 1
Sponsor
AffaMed Therapeutics Limited
Enrollment
21
Countries
United States
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
21
Population
ALL · 50 Years
Duration
2022-04-28 to 2024-11-04
Intervention
AM712(ASKG712)
Comparator
Not reported
Outcomes measured
Incidence of ocular adverse events (AEs) of the study eyes — 252 days; Incidence of non-ocular AEs — 252 days; Any relevant safety observations derived from BCVA — 252 days; Any relevant safety observations derived from SD-OCT — 252 days; Mean change from baseline in central subfield thickness as assessed by SD-OCT — 252 days; Proportion of patients with no intraretinal fluid, subretinal fluid, or pigment epithelial detachment as assessed by SD…; Mean change from baseline in BCVA (ETDRS) — 252 days; Proportion of patients gaining ≥ 15 letters from baseline BCVA — 252 days
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON